Your browser is no longer supported. Please, upgrade your browser.
Radius Health, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own16.00% Shs Outstand46.49M Perf Week-4.87%
Market Cap1.04B Forward P/E- EPS next Y-0.81 Insider Trans6.91% Shs Float46.46M Perf Month14.06%
Income-112.50M PEG- EPS next Q-0.44 Inst Own- Short Float13.43% Perf Quarter62.49%
Sales231.50M P/S4.51 EPS this Y40.80% Inst Trans0.47% Short Ratio13.56 Perf Half Y67.13%
Book/sh-2.34 P/B- EPS next Y65.10% ROA-56.90% Target Price22.25 Perf Year11.08%
Cash/sh2.61 P/C8.31 EPS next 5Y29.60% ROE134.60% 52W Range10.15 - 23.30 Perf YTD21.28%
Dividend- P/FCF- EPS past 5Y6.50% ROI-73.20% 52W High-5.60% Beta0.95
Dividend %- Quick Ratio2.20 Sales past 5Y- Gross Margin92.60% 52W Low116.73% ATR1.28
Employees383 Current Ratio2.20 Sales Q/Q66.20% Oper. Margin-37.80% RSI (14)67.27 Volatility6.31% 6.09%
OptionableYes Debt/Eq- EPS Q/Q79.20% Profit Margin-48.60% Rel Volume1.49 Prev Close21.66
ShortableYes LT Debt/Eq- EarningsNov 05 BMO Payout- Avg Volume459.93K Price22.00
Recom2.60 SMA208.44% SMA5026.04% SMA20054.91% Volume420,323 Change1.57%
Sep-29-20Resumed JP Morgan Neutral $23
Jul-08-20Downgrade SVB Leerink Outperform → Mkt Perform $17
May-13-20Downgrade Morgan Stanley Overweight → Equal-Weight $20
Apr-24-20Initiated Stifel Hold $20
Aug-29-19Upgrade Citigroup Neutral → Buy $24 → $40
May-30-19Resumed Citigroup Neutral
May-29-19Upgrade Goldman Neutral → Buy
Feb-14-19Initiated H.C. Wainwright Neutral $22
Mar-29-18Initiated Leerink Partners Outperform $53
Jan-29-18Initiated Morgan Stanley Overweight $57
Dec-06-17Initiated Citigroup Neutral $30
Oct-06-17Resumed Goldman Neutral
Mar-24-17Reiterated H.C. Wainwright Buy $71 → $66
Sep-21-16Reiterated H.C. Wainwright Buy $55 → $71
Aug-04-16Downgrade Maxim Group Hold → Sell $24
May-23-16Initiated H.C. Wainwright Buy $55
Mar-30-16Initiated Goldman Neutral
Feb-24-16Downgrade Jefferies Buy → Hold
Oct-02-15Initiated JP Morgan Overweight $88
Sep-24-15Reiterated Canaccord Genuity Buy $70 → $85
Jan-07-21 11:05AM  
Jan-06-21 12:00PM  
Jan-05-21 08:36AM  
Jan-04-21 04:30PM  
Dec-18-20 09:30PM  
Dec-15-20 09:00AM  
Dec-05-20 11:32AM  
Nov-09-20 10:21AM  
Nov-05-20 10:32PM  
Oct-29-20 12:35PM  
Oct-21-20 08:15AM  
Oct-20-20 04:15PM  
Oct-06-20 04:30PM  
Oct-05-20 12:46PM  
Oct-01-20 08:45AM  
Sep-25-20 06:15AM  
Sep-24-20 04:15PM  
Sep-09-20 11:30AM  
Sep-08-20 08:00AM  
Sep-02-20 04:15PM  
Aug-25-20 09:00AM  
Aug-10-20 09:01PM  
Aug-03-20 12:31PM  
Jul-27-20 04:15PM  
Jul-24-20 07:15AM  
Jul-23-20 04:15PM  
Jul-17-20 10:54AM  
Jun-16-20 10:44AM  
Jun-10-20 05:07PM  
Jun-06-20 11:31AM  
May-27-20 05:00AM  
May-08-20 04:46PM  
May-07-20 04:15PM  
Apr-30-20 12:34PM  
Apr-28-20 04:35PM  
Apr-20-20 04:15PM  
Apr-08-20 12:13PM  
Mar-28-20 11:30AM  
Mar-03-20 09:15AM  
Mar-02-20 07:47AM  
Feb-27-20 09:05AM  
Feb-26-20 08:36AM  
Feb-25-20 11:28AM  
Feb-20-20 12:31PM  
Feb-13-20 04:05PM  
Jan-22-20 06:36AM  
Jan-13-20 09:00AM  
Jan-09-20 01:30PM  
Jan-06-20 04:14PM  
Dec-12-19 09:36AM  
Dec-10-19 03:38PM  
Dec-06-19 09:47AM  
Dec-05-19 11:31AM  
Dec-02-19 04:52PM  
Nov-15-19 04:15PM  
Nov-09-19 10:21AM  
Nov-06-19 11:10AM  
Nov-05-19 08:05PM  
Oct-29-19 10:33AM  
Oct-27-19 06:42PM  
Oct-24-19 04:34AM  
Oct-23-19 05:37PM  
Sep-13-19 06:03PM  
Sep-09-19 10:48AM  
Sep-06-19 09:31AM  
Sep-03-19 09:00AM  
Aug-17-19 08:20AM  
Aug-08-19 10:24AM  
Aug-07-19 06:55PM  
Aug-05-19 04:00PM  
Jul-31-19 10:36AM  
Jul-23-19 09:00AM  
Jul-17-19 04:52PM  
Jul-03-19 01:44PM  
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; Guardant Health, Inc.; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerNov 05Buy14.26100,0001,426,2307,455,714Nov 09 11:29 AM
BIOTECH TARGET N V10% OwnerSep 14Buy11.69200,0002,338,6807,355,714Sep 16 12:01 PM
BIOTECH TARGET N V10% OwnerSep 11Buy11.33199,0292,255,1187,155,714Sep 14 04:03 PM
BIOTECH TARGET N V10% OwnerJul 08Buy13.2125,000330,1786,956,685Jul 09 02:40 PM
BIOTECH TARGET N V10% OwnerApr 30Buy15.7550,000787,5556,931,685May 04 05:32 PM
Dere Willard HDirectorFeb 26Sale17.951,92534,55412,195Feb 28 04:15 PM
Kelly Joseph FrancisSr. VP of Sales and MarketingFeb 26Sale17.9388915,94224,111Feb 28 04:15 PM
Carmona JoseChief Financial OfficerFeb 26Sale17.931,29223,16946,708Feb 28 04:15 PM
Rosenberg AnthonyDirectorFeb 26Sale17.951,81532,57912,401Feb 28 04:15 PM
Morris Charles QChief Medical OfficerFeb 26Sale17.931,25622,52433,744Feb 28 04:15 PM
Hughes OwenDirectorFeb 26Sale17.952,75049,36310,650Feb 28 04:15 PM